Amylyx Pharmaceuticals(AMLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AMLX Amylyx Pharmaceuticals

Closed 01-15 16:00:00 EST

13.52

-0.55

-3.91%

盘后13.52

+0.000.00%

19:44 EST

High14.26	Low13.22	Vol2.36M
Open14.13	D1 Closing14.07	Amplitude7.42%
Mkt Cap1.48B	Tradable Cap884.88M	Total Shares109.82M
T/O32.12M	T/O Rate3.61%	Tradable Shares65.45M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AMLX","market":"US","secType":"STK","nameCN":"Amylyx Pharmaceuticals","latestPrice":13.52,"timestamp":1768510800000,"preClose":14.07,"halted":0,"volume":2364905,"hourTrading":{"tag":"盘后","latestPrice":13.52,"preClose":13.52,"latestTime":"19:44 EST","volume":12563,"amount":169850.89,"timestamp":1768524291303},"delay":0,"floatShares":65449399,"shares":109819569,"eps":-1.774191,"marketStatus":"Closed","change":-0.55,"latestTime":"01-15 16:00:00 EST","open":14.13,"high":14.2642,"low":13.22,"amount":32120411.674075,"amplitude":0.074215,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.774191,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768554000000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1641531600000,"exchange":"NASDAQ","adjPreClose":14.07,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":14.3,"preClose":14.07,"latestTime":"09:08 EST","volume":385,"amount":5321.990135,"timestamp":1768486102399},"postHourTrading":{"tag":"盘后","latestPrice":13.52,"preClose":13.52,"latestTime":"19:44 EST","volume":12563,"amount":169850.89,"timestamp":1768524291303},"volumeRatio":1.558804,"impliedVol":0.5204,"impliedVolPercentile":0.4024},"requestUrl":"/m/hq/s/AMLX/wiki","defaultTab":"wiki","newsList":[{"id":"2602543356","title":"Amylyx Pharmaceuticals (AMLX) Valuation Check After AMX0318 Rare Disease Pipeline Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543356","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543356?lang=en_us&edition=fundamental","pubTime":"2026-01-12 19:15","pubTimestamp":1768216545,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals (AMLX) drew fresh investor attention after announcing AMX0318, a long-acting GLP-1 receptor antagonist, as a new development candidate for post-bariatric hypoglycemia and other rare diseases.\nSee our latest analysis for Amylyx Pharmaceuticals.\nThe AMX0318 announcement comes after a mixed stretch for the stock, with a 7-day share price return of 7.2% and a 30-day share price decline of 6.8%. The 1-year total shareholder return of about 3x suggests earlier momentum that...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/amylyx-pharmaceuticals-amlx-valuation-check-after-amx0318-ra","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/amylyx-pharmaceuticals-amlx-valuation-check-after-amx0318-ra","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","AMLX","DCF"],"gpt_icon":0},{"id":"2602131868","title":"Amylyx Co-CEO Justin Klee Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2602131868","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602131868?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:05","pubTimestamp":1767906352,"startTime":"0","endTime":"0","summary":"Justin B. Klee, Co-Chief Executive Officer and Director of Amylyx Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 08, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL3vpTHf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Amylyx Co-CEO Justin Klee Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2601536125","title":"Amylyx Pharmaceuticals Nominates AMX0318 as Candidate to Treat Post-Bariatric Hypoglycemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2601536125","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601536125?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:56","pubTimestamp":1767877007,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals  said Thursday that it has designated AMX0318 as a development candidate for post-bariatric hypoglycemia, and other rare diseases.The company said AMX0318 was selected as part of a research collaboration agreement with Danish preclinical contract research Gubra, which will receive a $4 million milestone payment for the selection.Under the terms of the collaboration, Gubra is eligible to receive more than $50 million in success-based development and commercialization milestones, as well as mid-single digit royalties on global net sales.Shares of Amylyx were up more than 3% pre-bell.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","POST","AMLX","BK4212"],"gpt_icon":0},{"id":"2601369626","title":"Amylyx selects AMX0318 as development candidate for PBH","url":"https://stock-news.laohu8.com/highlight/detail?id=2601369626","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601369626?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:16","pubTimestamp":1767874607,"startTime":"0","endTime":"0","summary":"Amylyx (AMLX) announced the selection of AMX0318, a long-acting glucagon-like peptide-1 receptor antagonist, as a development candidate for post-ba...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amylyx-selects-amx0318-as-development-candidate-for-pbh-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amylyx-selects-amx0318-as-development-candidate-for-pbh-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AMLX","PBH","BK4007"],"gpt_icon":0},{"id":"2601664633","title":"Amylyx Pharmaceuticals Advances AMX0318 as Long-Acting GLP-1 Receptor Antagonist for Rare Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2601664633","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601664633?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873645,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals Inc. has announced the nomination of AMX0318 as a novel, long-acting GLP-1 receptor antagonist development candidate, identified in collaboration with Gubra A/S. AMX0318 is being developed for post-bariatric hypoglycemia  and other rare diseases. The candidate has completed extensive preclinical evaluation, demonstrating robust stability, solubility, potency, in vivo pharmacokinetics and pharmacodynamics, and tolerability. Amylyx expects to advance AMX0318 into investigational new drug -enabling studies later this year, with an IND submission targeted for 2027, pending successful study completion. The results have not yet been presented; further development is ongoing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advic","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL2M7hcL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2601936619","title":"Amylyx Pharmaceuticals Announces Nomination of Amx0318 as a Novel, Long-Acting Glp-1 Receptor Antagonist Development Candidate, Identified in Collaboration With Gubra a/S","url":"https://stock-news.laohu8.com/highlight/detail?id=2601936619","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601936619?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA67HXV3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2601366146","title":"Amylyx Pharmaceuticals Inc - Gubra to Receive Over $50 Mln in Milestones and Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2601366146","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601366146?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA67HXV3:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2601003470","title":"Assessing Amylyx Pharmaceuticals (AMLX) Valuation After Insider Buying And AMX0114 Trial Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2601003470","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601003470?lang=en_us&edition=fundamental","pubTime":"2026-01-05 13:22","pubTimestamp":1767590562,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals (AMLX) is back in focus after a director bought more than $100,000 of company stock, alongside encouraging early safety data from its AMX0114 ALS program and an expansion of a related clinical trial.\nSee our latest analysis for Amylyx Pharmaceuticals.\nDespite the director buying and the AMX0114 updates, recent trading has been weak, with a 30 day share price return of a 19.58% decline and a 90 day return of a 15.34% decline, while the 1 year total shareholder return of...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/assessing-amylyx-pharmaceuticals-amlx-valuation-after-inside","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/assessing-amylyx-pharmaceuticals-amlx-valuation-after-inside","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","AMLX","DCF","PRGS","LU2065732104.USD","BK4097"],"gpt_icon":0},{"id":"2593447118","title":"Director Karen Firestone Acquires Common Shares of Amylyx Pharmaceuticals Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2593447118","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593447118?lang=en_us&edition=fundamental","pubTime":"2025-12-24 09:49","pubTimestamp":1766540956,"startTime":"0","endTime":"0","summary":"Karen Firestone, Director, reported the acquisition of common shares of Amylyx Pharmaceuticals Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 23, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251224:nNDL9b1Bgy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Karen Firestone Acquires Common Shares of Amylyx Pharmaceuticals Inc","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2590376183","title":"Is Amylyx Pharmaceuticals (AMLX) Overvalued After Its 250% Year‑to‑Date Share Price Surge?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590376183","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590376183?lang=en_us&edition=fundamental","pubTime":"2025-12-10 05:15","pubTimestamp":1765314907,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals (AMLX) has quietly staged a sharp rebound this year, with the stock up roughly 250% year to date and about 180% over the past year, drawing fresh attention from biotech investors.\nSee our latest analysis for Amylyx Pharmaceuticals.\nThe recent pullback, with a 1 day share price return of minus 3.7 percent and a 7 day share price return of minus 4.0 percent, looks more like a pause in what has been strong upward momentum, given the 30 day share price return of 11.1...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/is-amylyx-pharmaceuticals-amlx-overvalued-after-its-250-year","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/is-amylyx-pharmaceuticals-amlx-overvalued-after-its-250-year","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2589781231","title":"BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companies","url":"https://stock-news.laohu8.com/highlight/detail?id=2589781231","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589781231?lang=en_us&edition=fundamental","pubTime":"2025-12-06 03:14","pubTimestamp":1764962096,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companiesEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslette","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nL6N3XB0IL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PKG","HL","HUM","FCX","TARA","EXE","LU0128525689.USD","BMEA","TTAN","AUB","TE","WBD","PSN","XOM","DBRG","EUDA","VSCO","PRAX","RBRK","LU0320765646.SGD","LU1150488218.USD","IOT","OMC","ULTA","TRMB","FSLY","CHPT","LU0128525929.USD","LUV","FANG","INTS","EQT","HPE","ITT","ROL","CDE","DELL","ALB","AES","S","AMLX","SCCO","ZUMZ","COO"],"gpt_icon":1},{"id":"2589818089","title":"BUZZ-Amylyx rises after promising early-stage trial for ALS drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2589818089","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589818089?lang=en_us&edition=fundamental","pubTime":"2025-12-05 22:21","pubTimestamp":1764944492,"startTime":"0","endTime":"0","summary":"BUZZ-Amylyx rises after promising early-stage trial for ALS drug** Shares of drugmaker Amylyx Pharmaceuticals AMLX.O rise 1.8% to $14.75 premarket** Co says experimental drug, AMX0114, was generally well-tolerated by first group of patients in early-stage trial for amyotrophic lateral sclerosis, or ALS** ALS is a fatal condition that causes progressive muscle weakness and loss of movement, says co** Early-stage trial enrolled 12 patients, with no serious side effects linked to treatment - AMLX** Drug is injected into spinal fluid every four weeks; aims to protect nerve cells, co says** Second group enrollment to start in Canada this month and in January in the U.S. - AMLX** As of last close, stock up ~283% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nL4N3XB145:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"2589818522","title":"BRIEF-Amylyx Pharmaceuticals Announces New Safety And Tolerability Cohort 1 Data Of Amx0114","url":"https://stock-news.laohu8.com/highlight/detail?id=2589818522","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589818522?lang=en_us&edition=fundamental","pubTime":"2025-12-05 22:01","pubTimestamp":1764943311,"startTime":"0","endTime":"0","summary":"BRIEF-Amylyx Pharmaceuticals Announces New Safety And Tolerability Cohort 1 Data Of Amx0114 Dec 5 (Reuters) - Amylyx Pharmaceuticals Inc AMLX.O:AMYLYX PHARMACEUTICALS ANNOUNCES NEW SAFETY AND TOLERABI","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nTUA3HTJKX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2589818532","title":"Amylyx Reports Positive Early Safety Data for AMX0114 in ALS Phase 1 LUMINA Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2589818532","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589818532?lang=en_us&edition=fundamental","pubTime":"2025-12-05 22:00","pubTimestamp":1764943245,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals Inc. announced early safety and tolerability data from its Phase 1 LUMINA trial of AMX0114, an investigational antisense oligonucleotide targeting calpain-2, in people with amyotrophic lateral sclerosis . The data from the first cohort  were presented at the 36th International Symposium on ALS/MND held December 5-7, 2025, in San Diego, California. According to the company, AMX0114 was generally well-tolerated, with no treatment-related serious adverse events reported. Based on these findings, enrollment for the second cohort is expected to begin in Canada later this month and in the U.S. in January. Amylyx plans to present biomarker data from the first cohort in the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investmen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL1Tbk9C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2589818591","title":"Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of Amx0114 in ALS From First-in-Human Lumina Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2589818591","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589818591?lang=en_us&edition=fundamental","pubTime":"2025-12-05 22:00","pubTimestamp":1764943202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nTUA3HTJKX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2589818516","title":"Amylyx Pharmaceuticals Inc - Amx0114 Well-Tolerated With No Serious Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2589818516","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589818516?lang=en_us&edition=fundamental","pubTime":"2025-12-05 22:00","pubTimestamp":1764943202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nTUA3HTJKX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"2588024054","title":"Amylyx Pharmaceuticals Chief Medical Officer Camille L. Bedrosian Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588024054","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588024054?lang=en_us&edition=fundamental","pubTime":"2025-12-04 05:40","pubTimestamp":1764798027,"startTime":"0","endTime":"0","summary":"Camille L. Bedrosian, Chief Medical Officer of Amylyx Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDLbrrlfj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Amylyx Pharmaceuticals Chief Medical Officer Camille L. Bedrosian Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"2584926436","title":"Amylyx Pharmaceuticals Q3 EPS USD -0.37 Vs. IBES Estimate USD -0.47","url":"https://stock-news.laohu8.com/highlight/detail?id=2584926436","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584926436?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:52","pubTimestamp":1763571155,"startTime":"0","endTime":"0","summary":"Nov 06 (Reuters) - Amylyx Pharmaceuticals Q3 operating income USD -36.027 million vs. IBES estimate USD -43.1 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202511:00:00.293 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD2fmpBP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2583451154","title":"Is Amylyx (AMLX) Reshaping Its Investment Case With Improved Losses and Avexitide’s Path to Market?","url":"https://stock-news.laohu8.com/highlight/detail?id=2583451154","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583451154?lang=en_us&edition=fundamental","pubTime":"2025-11-14 02:36","pubTimestamp":1763059000,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals recently reported third quarter 2025 results, revealing a reduction in net loss to US$34.39 million, down from US$72.7 million a year earlier, and provided updates on its clinical pipeline including adjusted timelines for the pivotal Phase III LUCIDITY trial.\nAn important development is the progress toward a potential commercial launch for avexitide in 2027, reflecting the company's forward-looking investment in market readiness despite near-term trial delays.\nWe'll...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/is-amylyx-amlx-reshaping-its-investment-case-with-improved-l","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/is-amylyx-amlx-reshaping-its-investment-case-with-improved-l","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"1195243245","title":"Stock Track | Amylyx Pharmaceuticals Soars Nearly 7% as Mizuho Boosts Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1195243245","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195243245?lang=en_us&edition=fundamental","pubTime":"2025-11-10 22:32","pubTimestamp":1762785172,"startTime":"0","endTime":"0","summary":"Shares of Amylyx Pharmaceuticals (AMLX) are surging in Monday's pre-market session, climbing 6.99% following a significant price target upgrade from Mizuho analysts. The biotechnology company, which...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AMLX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.amylyx.com","stockEarnings":[{"period":"1week","weight":0.1735},{"period":"1month","weight":0.1202},{"period":"3month","weight":-0.0725},{"period":"6month","weight":0.6871},{"period":"1year","weight":3.4952},{"period":"ytd","weight":0.1647}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0141},{"period":"3month","weight":0.045},{"period":"6month","weight":0.1},{"period":"1year","weight":0.1858},{"period":"ytd","weight":0.0124}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.069481},{"month":2,"riseRate":0.5,"avgChangeRate":0.096144},{"month":3,"riseRate":0.25,"avgChangeRate":-0.384218},{"month":4,"riseRate":0.25,"avgChangeRate":-0.062706},{"month":5,"riseRate":0.25,"avgChangeRate":-0.046188},{"month":6,"riseRate":0.75,"avgChangeRate":0.347356},{"month":7,"riseRate":1,"avgChangeRate":0.206362},{"month":8,"riseRate":0.5,"avgChangeRate":0.025088},{"month":9,"riseRate":0.75,"avgChangeRate":0.218209},{"month":10,"riseRate":0.75,"avgChangeRate":0.212399},{"month":11,"riseRate":0.75,"avgChangeRate":0.011294},{"month":12,"riseRate":0.25,"avgChangeRate":-0.127185}],"exchange":"NASDAQ","name":"Amylyx Pharmaceuticals","nameEN":"Amylyx Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Amylyx Pharmaceuticals(AMLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Amylyx Pharmaceuticals(AMLX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Amylyx Pharmaceuticals,AMLX,Amylyx Pharmaceuticals股票,Amylyx Pharmaceuticals股票老虎,Amylyx Pharmaceuticals股票老虎国际,Amylyx Pharmaceuticals行情,Amylyx Pharmaceuticals股票行情,Amylyx Pharmaceuticals股价,Amylyx Pharmaceuticals股市,Amylyx Pharmaceuticals股票价格,Amylyx Pharmaceuticals股票交易,Amylyx Pharmaceuticals股票购买,Amylyx Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Amylyx Pharmaceuticals(AMLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Amylyx Pharmaceuticals(AMLX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction